These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 32201860)

  • 21. Clinical efficacy, drug sustainability and serum drug levels in Crohn's disease patients treated with ustekinumab - A prospective, multicenter cohort from Hungary.
    Gonczi L; Szanto K; Farkas K; Molnar T; Szamosi T; Schafer E; Golovics PA; Barkai L; Lontai L; Lovasz B; Juhasz M; Patai A; Sarang K; Vincze A; Sarlos P; Farkas A; Dubravcsik Z; Toth TG; Miheller P; Ilias A; Lakatos PL
    Dig Liver Dis; 2022 Feb; 54(2):207-213. PubMed ID: 34344576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli study.
    Bar-Gil Shitrit A; Ben-Ya'acov A; Siterman M; Waterman M; Hirsh A; Schwartz D; Zittan E; Adler Y; Koslowsky B; Avni-Biron I; Chowers Y; Ron Y; Israeli E; Ungar B; Yanai H; Maharshak N; Ben-Horin S; Eliakim R; Dotan I; Goldin E; Kopylov U
    United European Gastroenterol J; 2020 May; 8(4):418-424. PubMed ID: 32213026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationships of capsule endoscopy Lewis score with clinical disease activity indices, C-reactive protein, and small bowel transit time in pediatric and adult patients with small bowel Crohn's disease.
    He C; Zhang J; Chen Z; Feng X; Luo Z; Wan T; Li A; Liu S; Ren Y
    Medicine (Baltimore); 2017 Aug; 96(33):e7780. PubMed ID: 28816962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation and comparison of capsule endoscopy scores for assessment of inflammatory activity of small-bowel in Crohn's disease.
    Ponte A; Pinho R; Rodrigues A; Silva J; Rodrigues J; Sousa M; Carvalho J
    Gastroenterol Hepatol; 2018 Apr; 41(4):245-250. PubMed ID: 29249271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates.
    Verstockt B; Dreesen E; Noman M; Outtier A; Van den Berghe N; Aerden I; Compernolle G; Van Assche G; Gils A; Vermeire S; Ferrante M
    J Crohns Colitis; 2019 Jul; 13(7):864-872. PubMed ID: 30715258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comprehensive review and update on Crohn's disease.
    Gajendran M; Loganathan P; Catinella AP; Hashash JG
    Dis Mon; 2018 Feb; 64(2):20-57. PubMed ID: 28826742
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of Paediatric Patients With Medically Refractory Crohn's Disease Using Ustekinumab: A Multi-Centred Cohort Study.
    Chavannes M; Martinez-Vinson C; Hart L; Kaniki N; Chao CY; Lawrence S; Jacobson K; Hugot JP; Viala J; Deslandres C; Jantchou P; Seidman EG
    J Crohns Colitis; 2019 Apr; 13(5):578-584. PubMed ID: 30541021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience.
    Wils P; Bouhnik Y; Michetti P; Flourie B; Brixi H; Bourrier A; Allez M; Duclos B; Serrero M; Buisson A; Amiot A; Fumery M; Roblin X; Peyrin-Biroulet L; Filippi J; Bouguen G; Abitbol V; Coffin B; Simon M; Laharie D; Pariente B;
    Aliment Pharmacol Ther; 2018 Mar; 47(5):588-595. PubMed ID: 29315694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of ustekinumab in real clinical practice. Retrospective multicentre study. ARAINF cohort.
    Casas Deza D; García López S; Lafuente Blasco M; Vicente Lidón R; Nerín de la Puerta J; Peña Gonzalez E; Ber Nieto Y; Charro Calvillo M; Alcalá Escriche MJ; Gomollón García F; Arroyo Villarino M
    Gastroenterol Hepatol; 2020 Mar; 43(3):126-132. PubMed ID: 31866167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ustekinuma b for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study.
    Straatmijer T; Biemans VBC; Hoentjen F; de Boer NKH; Bodelier AGL; Dijkstra G; van Dop WA; Haans JJL; Jansen JM; Maljaars PWJ; van der Marel S; Oldenburg B; Ponsioen CY; Visschedijk MC; de Vries AC; West RL; van der Woude CJ; Pierik M; Duijvestein M; van der Meulen-de Jong AE
    J Crohns Colitis; 2021 Nov; 15(11):1920-1930. PubMed ID: 33909062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. One-year real life data of our patients with moderate-severe Crohn's disease who underwent ustekinumab therapy.
    Bacaksız F; Arı D; Gökbulut V; Öztürk Ö; Kayaçetin E
    Scott Med J; 2021 Aug; 66(3):152-157. PubMed ID: 33832363
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravenous Ustekinumab Reinduction Is Effective in Prior Biologic Failure Crohn's Disease Patients Already on Every-4-Week Dosing.
    Sedano R; Guizzetti L; McDonald C; Jairath V
    Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1497-1498.e1. PubMed ID: 32763479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
    Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ustekinumab in Crohn's disease: Real-world outcomes from the Sicilian network for inflammatory bowel diseases.
    Viola A; Muscianisi M; Macaluso FS; Ventimiglia M; Cappello M; Privitera AC; Magnano A; Pluchino D; Magrì G; Ferracane C; Mocciaro F; Garufi S; Giuffrida E; Costantino G; Fiocco G; Grova M; Guida L; Alibrandi A; Orlando A; Fries W;
    JGH Open; 2021 Mar; 5(3):364-370. PubMed ID: 33732883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Visceral adiposity and inflammatory bowel disease.
    Rowan CR; McManus J; Boland K; O'Toole A
    Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.
    Hu A; Kotze PG; Burgevin A; Tan W; Jess A; Li PS; Kroeker K; Halloran B; Panaccione R; Peyrin-Biroulet L; Ma C; Ananthakrishnan AN
    Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1366-1376.e2. PubMed ID: 32668338
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Normalization of long-term quality of life in Crohn's disease patients receiving ustekinumab.
    Marquès-Camí M; Robles Alonso V; Borruel N; Herrera de Guise C; Mayorga L; Casellas F
    Rev Esp Enferm Dig; 2021 May; 113(5):313-317. PubMed ID: 33213168
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of Ustekinumab Failure in Crohn's Disease After Dose Intensification.
    Dalal RS; Njie C; Marcus J; Gupta S; Allegretti JR
    Inflamm Bowel Dis; 2021 Jul; 27(8):1294-1301. PubMed ID: 33146703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort.
    Khorrami S; Ginard D; Marín-Jiménez I; Chaparro M; Sierra M; Aguas M; Sicilia B; García-Sánchez V; Suarez C; Villoria A; Taxonera C; Velasco-Guardado A; Martínez-González J; Gisbert JP
    Inflamm Bowel Dis; 2016 Jul; 22(7):1662-9. PubMed ID: 27306072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy.
    Bermejo F; Jiménez L; Algaba A; Vela M; Bastida G; Merino O; López-García A; Melcarne L; Rodríguez-Lago I; de la Maza S; Bouhmidi A; Barreiro-de Acosta M; López-Serrano P; Carrillo-Palau M; Mesonero F; Orts B; Bonillo D; Granja A; Guerra I
    Inflamm Bowel Dis; 2022 Jan; 28(1):41-47. PubMed ID: 33528018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.